OBI-3424 receives orphan designation for ALL

Micrograph showing T-ALL
© Hind Medyouf, German
Cancer Research Center
The U.S. Food and Drug Administration (FDA) has granted orphan drug designation to OBI-3424 for the treatment of acute lymphoblastic leukemia (ALL). OBI-3424 is a small-molecule prodrug that targets cancers overexpressing aldo-keto reductase 1C3 (AKR1C3) and selectively releases a DNA alkylating agent in the presence of the AKR1C3 enzyme. AKR1C3 overexpression has been observed in ALL, particularly T-cell ALL. [Read Article]

Guidelines for proton therapy in mediastinal lymphomas

Treatment room at the
Roberts Proton Therapy
Center at the University
of Pennsylvania.
Photo from Penn Medicine
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to derive the most benefit, according to new guidelines from the International Lymphoma Radiation Oncology Group. The guidelines note that proton therapy reduces the radiation dose to organs at risk in certain clinical presentations, such as when the mediastinal target is on both sides of the heart. [Read Article]

AKT inhibitor exhibits activity against MM

Micrograph showing MM
Preclinical research suggests an AKT inhibitor could be effective against multiple myeloma (MM). The inhibitor, HS1793, is a derivative of the antioxidant compound resveratrol. Investigators found that HS1793 decreased AKT signaling to induce mitochondria-mediated cell death in MM cells. HS1793 was cytotoxic to MM cells in a mouse model of human metastatic myeloma and in human MM cells in vitro. [Read Article]